Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
08/2003
08/28/2003US20030162765 Use in treatment and prevention of central nervous system and other disorders
08/28/2003US20030162759 Preventing or treating cardiovascular disease including atherosclerosis
08/28/2003US20030162701 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
08/28/2003US20030162196 Isolation nucleic acids; genetic engineering; diagnosis, therapy, prevention hematopoietic, nervous system disorders
08/28/2003US20030162194 Diagnosis of diseases associated with apoptosis
08/28/2003US20030162175 NK cell receptor polynucleotides, polypeptides, and antibodies
08/28/2003US20030161884 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/28/2003US20030161826 Therapy for autoimmune disease; central nervous system disorders
08/28/2003US20030161816 Systems and methods for treating patients with processed lipoaspirate cells
08/28/2003US20030159953 Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof
08/28/2003CA2476822A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
08/28/2003CA2476434A1 Method of treating trx mediated diseases
08/28/2003CA2476411A1 Thiazolyl urea compounds for the treatment of cancer
08/28/2003CA2476406A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
08/28/2003CA2476402A1 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
08/28/2003CA2476115A1 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
08/28/2003CA2476112A1 Rna interference mediated inhibition of interleukin gene expression using short interfering nucleic acid (sina)
08/28/2003CA2475374A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
08/28/2003CA2474848A1 Novel tyloindicines and related processes, pharmaceutical compositions and methods
08/28/2003CA2459532A1 Rna interference by modified short interfering nucleic acid
08/28/2003CA2456444A1 Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina)
08/28/2003CA2419685A1 Antidiabetic agents
08/27/2003EP1338600A1 Fused 1,2,4-Thiadiazine derivatives, their preparation and use
08/27/2003EP1338597A1 1,4,5,6-tetrahydroimidazo 4,5-d]diazepine derivatives or salts thereof
08/27/2003EP1337560A2 Truncated cd200
08/27/2003EP1337558A2 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor
08/27/2003EP1337544A2 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme
08/27/2003EP1337527A1 Indolylmaleimide derivatives as protein kinase c inhibitors
08/27/2003EP1337521A1 Salts of an isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
08/27/2003EP1337518A1 Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
08/27/2003EP1337512A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
08/27/2003EP1337283A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency
08/27/2003EP1337272A2 Combination of gaba agonists and aldose reductase inhibitors
08/27/2003EP1337271A2 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
08/27/2003EP1337256A2 Use of thienopyrimidines
08/27/2003EP1337254A2 Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence
08/27/2003EP1337253A1 Novel compounds
08/27/2003EP1337246A2 Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
08/27/2003EP1337243A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide
08/27/2003EP1140938B1 High affinity inhibitors for target validation and uses thereof
08/27/2003EP1140889B1 Compounds and methods for modulation of estrogen receptors
08/27/2003EP1042368B1 Antibodies against phosphorylated vasp (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use
08/27/2003EP1007520B1 2-aminopyridines containing fused ring substituents as nos inhibitors
08/27/2003EP0891363B1 Heterocyclic compounds and their preparation and use
08/27/2003CN1439021A Parathyroid hormone and parathyroid hormone-related protein receptor modulators
08/27/2003CN1438996A Bicyclic cyclohexylamines and their use NMDA receptor antogonists
08/27/2003CN1438893A Therapeutical use of sophora flavescens or sophora subprostrated extracts
08/27/2003CN1438885A Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators
08/27/2003CN1438861A Minimizing adverse experience associated with oxybutynin therapy
08/27/2003CN1438216A Method for increasing citrulline and hyperplasia-resisting factor active matter content in pumpkin seeds and method for extracting same
08/27/2003CN1438019A Method for supercritical fluid extraction of hyper plasia-resistant factor active matter in pumpkin seed
08/27/2003CN1438016A Medicine for treating non-gonococcal vaginitis and preparation method
08/27/2003CN1437949A Use of Rhizoma Dioscoreae Nipponicae and its dioscorea saponin in treating chronic glomerulus nephritis
08/27/2003CN1437943A Compound injection of levocarnitine and vitamin B6
08/27/2003CN1119416C Human interleukin 2 derivatives and human heart sodium medium fusion gene, its protein products and uts thereof
08/27/2003CN1119340C Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
08/27/2003CN1119313C Inhibition of matrix metallo proteases by 2-(omega-aroylalkyc)-4-biaryl-oxobutyric acids
08/27/2003CN1119164C Medicine for treating chronic pncomplete renal function and its preparation
08/27/2003CN1119148C Use of alpha 1L agonists in treatment of in continence
08/27/2003CN1119146C Compositions and kits for increasing the oral bioavailability of pharmaceutical agents
08/26/2003US6610821 Cyclic peptide of given amino acid sequence; can use to improve drug delivery process, inhibit angiogenesis, increase vasopermeability; treatment of autoimmune and inflammatory diseases
08/26/2003US6610737 Non-psychotropic cannabinoids
08/26/2003US6610735 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide)
08/26/2003US6610719 Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure
08/26/2003US6610716 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
08/26/2003US6610695 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease
08/26/2003US6610691 Carboxylic acid derivatives, their production and use
08/26/2003US6610690 Administering optically pure (S,S) enantiomer of reboxetine
08/26/2003US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
08/26/2003US6610523 Human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating
08/26/2003US6610320 Mixture of cocoa plant extract and antichloesterol agent
08/21/2003WO2003068983A1 Use of the axl receptor for diagnosis and treatment of renal disease
08/21/2003WO2003068959A1 Novel screening method
08/21/2003WO2003068817A1 Management of mucosal viscosity by tff monomer peptides
08/21/2003WO2003068811A2 Cytotoxic t-cell epitopes from chlamydia
08/21/2003WO2003068769A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
08/21/2003WO2003068759A1 Piperazine derivatives as anti-inflammatory agents
08/21/2003WO2003068750A1 Jnk inhibitor
08/21/2003WO2003068749A1 Vanilloid receptor modulators
08/21/2003WO2003068747A1 Nicotinamide derivates useful as p38 inhibitors
08/21/2003WO2003068743A1 Chemical compounds
08/21/2003WO2003068725A2 Process for the preparation of 4-hetero-substituted phenylalanine derivatives
08/21/2003WO2003068237A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068230A1 Substituted pyridinones as modulators of p38 map kinase
08/21/2003WO2003068226A1 2-oxazolamines and their use as 5-ht2b receptor antagonists
08/21/2003WO2003068218A1 Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k
08/21/2003WO2003068217A1 Biphenil derivatives and their use as antiandrogenic agents
08/21/2003WO2003068210A1 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
08/21/2003WO2003068202A1 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
08/21/2003WO2003068193A1 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
08/21/2003WO2003068171A2 Method and composition for treatment of inflammation and aids-associated neurological disorders
08/21/2003WO2003068146A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003044056A3 Chemically-modified human growth hormone conjugates
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
08/21/2003WO2002085384A3 Lubricious coatings for substrates
1 ... 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 ... 562